A58Elevance Health, Inc.

🇩🇪 Xetra
367.70
EUR
Analysis Scores
Lothien Robustness Score?
72/100
Very Strong
Neden bu skor?
Damodaran ?
51/100
ROIC hesaplanamadı: bilançoda TTM faaliyet kârı (esas faaliyet kârı) kalemi yok; DCF hesaplanamadı (faaliyet kârı veya nakit akışı eksik)
Dalio Risk ?
77/100
Piotroski ?
5/9
Neutral
Previous period ROA data missing (C1 delta-ROA); Current ratio data missing (C6); gross profit data missing → margin comparison unavailable (C8); Banka/finans: kaldıraç/cari-oran/marj kriterleri uygulanamaz, skor kalan kriterlere göre normalize edildi
Graham ?
€289.9
Pahalı
Active Metric?
3/4
Confidence?
74%
Lothien Robustness Summary
56/100
Lothien Sağlamlık: Orta (56/100)
Karışık sinyaller. Hem olumlu hem olumsuz göstergeler mevcut. | Kısa Vade: Olumsuz | Uzun Vade: Nötr | Pozitif: 4 | Negatif: 2 | Nötr: 1
Net Kâr Pozitif
Son çeyrekte €1.3B net kâr açıklandı. Şirket kârlı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%-17.1). İstikrarlı seyir.
3 Çeyrek Üst Üste Düşüş
Son 3 çeyrek üst üste kâr düşüyor. Aşağı trend endişe verici. Sonraki çeyreğe dikkat.
Çok Düşük Net Kâr Marjı
Net kâr marjı sadece %2.9. Küçük bir maliyet artışı şirketi zarara sokabilir.
Güçlü Nakit Üretimi
Serbest nakit akışı (€1.4B) kârın %111'sini nakit olarak üretiyor. Kâr kalitesi yüksek.
Düşük EV/EBITDA
EV/EBITDA: 2.9. Operasyonel kârlılığa göre ucuz değerleme.
Lothien Sağlamlık Skoru: 72/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı güçlü görünüyor.

Data date 2026-11-19 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-19
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Yüksek
252 days
Annual Volatility ?
%45.8
VaR 95% ?
%4.64
daily max loss
VaR 99% ?
%6.60
daily max loss
CVaR 95% ?
%5.56
expected loss (tail)
Max Drawdown ?
%25.6
16.01.2026 → 09.03.2026
Skewness ?
2.61
Parametrik%4.64
Historik%3.00
Cornish-Fisher%0.57
Return Distribution
Valuation
Potential?
+84.9%
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/9
Son 5 çeyrek ardışık kâr
Fiyat TRAMA-99 üzerinde: %+6.8 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 344.13 EUR
Fundamental & Technical Analysis
Profitability
Net Profit Margin %2.9
Net profit margin %2.9 — positive but low. Compared to previous quarter -0.6 point decrease.
ROE - Return on Equity (TTM) %8.5
ROE %8.5 — low return on equity.
EBITDA Margin %18.6
EBITDA margin %18.6 — good operational performance.
Gross Profit Margin %116.6
Gross profit per revenue %116.6. Strong pricing power.
Free Cash Flow Margin (TTM) %3.1
TTM Free Cash Flow is %3.1'i. Moderate FCF — capex constraining operational profit.
Valuation
P/E Ratio 18.1x Sector: 26.6x
F/K 18.1x — sector median's (26.6x) %32 below. Attractive for value investing.
P/B Ratio 2.00x Sector: 3.97x
PD/DD 2.00x — sector median's (3.97x) well below. Cheap relative to book value.
EV/EBITDA 2.9x Sector: 15.1x
EV/EBITDA 2.9x — sector median's (15.1x) %80 below. Cheap relative to EBITDA.
Indebtedness
Net Debt / EBITDA 0.8x
Net Debt/EBITDA 0.8x — very low debt burden. Company can repay debt quickly.
Debt / Equity 0.69x
Debt/Equity 0.69x — moderate financial leverage.
Interest Coverage 26.1x
Interest coverage 26.1x — very wide margin for paying interest expenses.
Growth
Revenue Growth (YoY) %+1.4
Revenue YoY %1.4 grew — positive but slow growth.
Net Profit Growth (YoY) %-16.1
Net profit YoY %-16.1 declined — profitability under pressure.
Score Explanations
Lothien Robustness
72/100
Very strong robustness score (72/100). Damodaran valuation, Dalio risk analysis and balance sheet quality criteria are largely met.
Very Strong
Potential
+84.9%
Plus %84.9 expected value (679.78) vs current price comparison. 3/4 valuation models could be calculated. Model confidence %74.
Components: PE target: 559.17 | P/B target: 752.09 | EV/EBITDA target: 1103.10
Damodaran Valuation
51/100
Moderate
Dalio Risk Analysis
77/100
Low debt risk (77/100). Interest coverage ratio 26.1x — strong. Debt/EBITDA 0.8x — in healthy range.
Leverage: 74/100 | Debt Service: 100/100 | Quality: 86/100
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
5/9
Moderate Piotroski (5/9). Some balance sheet criteria met, some missing. Note: Previous period ROA data missing (C1 delta-ROA); Current ratio data missing (C6)
Neutral
Graham Intrinsic Value
€289.9
Expensive
⚖️ Sector Comparison
P/E Ratio
18.1x vs 26.6x
Sector median's %32 below — cheap
P/B Ratio
2.00x vs 3.97x
Compared to sector %50 cheaper (by book value)
EV/EBITDA
2.9x vs 15.1x
Compared to sector %80 lower EV/EBITDA
Net Profit Margin (TTM)
%2.5 vs %18.6 EBITDA margin
TTM net profit margin %2.5
TRAMA-99 Trend — Uptrend
Price (367.70), TRAMA-99 line's %6.8 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 367.70
TRAMA: 344.13
Difference: %+6.8
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
A58 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.